Treatment of psoriasis with efalizumab in patients with hepatitis C viral infection: Report of five cases

Dermatology

Volumn 219, Issue 2, 2009, Pages 158-161

  Gisondi, Paolo ^a   Prignano, Francesca ^b   Grossi, Paolo ^c   Lotti, Torello ^b   Girolomoni, Giampiero ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Efalizumab; Hepatitis C virus infection; Psoriasis

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS C ANTIBODY; ISONIAZID; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; COMORBIDITY; DEMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; GINGIVA HYPERTROPHY; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPERTENSION; LIVER BIOPSY; LIVER DISEASE; MALE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUVA; RADIATION DOSE; RETROSPECTIVE STUDY; SIDE EFFECT; ULTRAVIOLET B RADIATION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RISK ASSESSMENT; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 69349092309     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000224433     Document Type: Article

References (40)

1. Christophers E: Comorbidities in psoriasis. Clin Dermatol 2007; 25: 529-534.
2. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni G: Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based casecontrol study. Br J Dermatol 2007; 157: 68-73. (Pubitemid 46934281)
3. Girolomoni G, Gisondi P: Psoriasis and metabolic comorbidities: the importance of well-designed prospective studies. Dermatology 2008; 217: 222-224. (Pubitemid 351158577)
4. Gottlieb AB, Chao C, Dann F: Psoriasis comorbidities. J Dermatol Treat 2008; 19: 5-21.
5. Azfar RS, Gelfand JM: Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 2008; 20: 416-422.
6. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG: National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031-1042.
7. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ: The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
8. Rantala M, van de Laar MJ: Surveillance and epidemiology of hepatitis B and C in Europe - a review. Euro Surveill 2008; 13: 18880.
9. Ansaldi F, Bruzzone B, Salmaso S, Rota MC, Durando P, Gasparini R, Icardi G: Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 2005; 76: 327-332. (Pubitemid 40770887)
10. Taglione E, Vatteroni ML, Martini P, Galluzzo E, Lombardini F, Delle Sedie A, Bendinelli M, Pasero G, Bencivelli W, Riente L: Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. J Rheumatol 1999; 26: 370-372. (Pubitemid 29066741)
11. Chouela E, Abeldaño A, Panetta J, Ducard M, Neglia V, Sookoian S, Kina M, Castaño G, Vereytou F, Frider B: Hepatitis C virus antibody (anti-HCV): prevalence in psoriasis. Int J Dermatol 1996; 35: 797-799. (Pubitemid 26391832)
12. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R: Guidelines of care for the management of psoriasis and psoriatic arthritis. 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850.
13. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B: Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2007; 5(suppl 3):1-119.
14. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD: British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486-497. (Pubitemid 41248202)
15. Krueger JG, Ochs HD, Patel P, Gilkerson E, Guttman-Yassky E, Dummer W: Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study. J Invest Dermatol 2008; 128: 2615-2624.
16. Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB: Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008; 158: 1107-1116.
17. Gisondi P, Girolomoni G: Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007; 6: 515-519. (Pubitemid 47374611)
18. Nathan DM, Angus PW, Gibson PR: Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006; 21: 1366-1371.
19. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consensus and State-of-the-Science Statements 2002; 19: 3. http://consensus.nih.gov/ about/process.htm.
20. Bravo AA, Sheth SG, Chopra S: Liver biopsy. N Engl J Med 2001; 344: 495-500.
21. Vento S, Cainelli F, Longhi MS: Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002; 3: 333-340. (Pubitemid 34661982)
22. Georgetson MJ, Yarze JC, Lalos AT, Webster GF, Martin P: Exacerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis. Am J Gastroenterol 1993; 88: 1756-1758. (Pubitemid 23298128)
23. Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, Chen CH, Kakinuma S, Oooka S, Maekawa S, Enomoto N, Watanabe M: Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 2005; 129: 1031-1041. (Pubitemid 41242693)
24. Galeazzi M, Bellisai F, Giannitti C, Manganelli S, Morozzi G, Sebastiani GD: Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection. Ann NY Acad Sci 2007; 1110: 544-549. (Pubitemid 350043044)
25. Galeazzi M, Giannitti C, Manganelli S, Benucci M, Scarpato S, Bazzani C: Treatment of rheumatic diseases in patients with HCV and HIV infection. Autoimmun Rev 2008; 8: 100-103.
26. Kallinowski B, Haseroth K, Marinos G, Hanck C, Stremmel W, Theilmann L, Singer MV, Rossol S: Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998; 111: 269-277. (Pubitemid 28088306)
27. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, Burra P, Floreani A, Cecchetto A, Naccarato R: Iron storage, lipid peroxidation and glutathion turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22: 449-456.
28. Zein NN: Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42: 315-322.
29. Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, Triolo G, Valentini G, Valesini G: Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008; 35: 1944-1949.
30. Piccolo D, Cesare AD, Fargnoli MC, Paoloni M, Vecchiotti S, Peris K: Effective control of psoriasis by etanercept in a patient with HCV-related diseases. Eur J Dermatol 2008; 18: 459-460. (Pubitemid 352031859)
31. Cecchi R, Bartoli L: Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept). Dermatol Online J 2006; 12: 4. (Pubitemid 44954024)
32. Magliocco MA, Gottlieb AB: Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004; 51: 580-584.
33. De Simone C, Paradisi A, Capizzi R, Carbone A, Siciliano M, Amerio PL: Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 2006; 54: 1102-1104. (Pubitemid 43732395)
34. Domm S, Cinatl J, Mrowietz U: The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008; 159: 1217-1228.
35. Langley RG, Carey WP, Rafal ES, Tyring SK, Caro I, Wang X, Wetherill G, Gordon KB: Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther 2005; 27: 1317-1328. (Pubitemid 41598367)
36. Balato A, Balato N, Patruno C, Gallo L, Ayala F: Visceral leishmaniasis infection in a patient with psoriasis treated with efalizumab. Dermatology 2008; 217: 360-361.
37. Weisenseel P, Kuznetsov AV, Flaig M, Prinz JC: Disseminated eruptive giant mollusca contagiosa in an adult psoriasis patient during efalizumab therapy. Dermatology 2008; 217: 85-86. (Pubitemid 351896578)
38. Caudron A, Lok C, Clabaut A, Desblache J, Heyman B, Viseux V: Cytomegalovirus colitis in a patient treated with efalizumab. Dermatology 2009; 218: 84-85.
39. Livio F, Ivanyuk A, Biollaz J: Pharmacovigilance and teratogen 2008. Rev Med Suisse 2009; 5: 130-134.
40. http://www.emea.europa.eu/humandocs/ PDFs/EPAR/raptiva/2085709en.pdf.